US 12,285,463 B2
Modulation of tumor immunity by protein-mediated O2 delivery
Stephen P. L. Cary, San Mateo, CA (US); Ana Krtolica, San Francisco, CA (US); Natacha Le Moan, San Francisco, CA (US); Jonathan A Winger, Oakland, CA (US); and Kevin G. Leong, Millbrae, CA (US)
Assigned to Omniox, Inc., San Francisco, CA (US)
Filed by Omniox, Inc., San Carlos, CA (US)
Filed on Dec. 10, 2021, as Appl. No. 17/547,748.
Application 17/547,748 is a continuation of application No. 15/558,957, abandoned, previously published as PCT/US2016/022981, filed on Mar. 17, 2016.
Claims priority of provisional application 62/134,523, filed on Mar. 17, 2015.
Prior Publication US 2022/0160823 A1, May 26, 2022
Int. Cl. A61K 38/16 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61N 5/10 (2006.01)
CPC A61K 38/164 (2013.01) [A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01); A61N 5/10 (2013.01); A61N 2005/1098 (2013.01)] 18 Claims
 
1. A method for treating cancer in a human individual having cancer comprising: (a) administering to the individual an effective amount of a trimeric H-NOX protein, wherein the trimeric H-NOX protein comprises three monomers, wherein the monomers each comprise a T tengcongensis H-NOX domain and a trimerization domain, wherein each of the three monomers is covalently bound to polyethylene glycol (PEG), wherein each T tengcongensis H-NOX domain has the amino acid sequence of SEQ ID NO:2 except for a L144F amino acid substitution in SEQ ID NO:2, and wherein the trimerization domain is a foldon domain of bacteriophage T4 fibritin; and (b) administering to the individual an immunotherapy, wherein the immunotherapy is an anti-PD-1 antibody therapy, or a dual PD-1/PD-L1 blockade antibody therapy; and wherein the cancer is glioblastoma.